Upstream Bio, Inc. (UPB)
| Market Cap | 436.63M -9.7% |
| Revenue (ttm) | 2.80M +26.8% |
| Net Income | -135.82M |
| EPS | -2.62 |
| Shares Out | 54.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,597,516 |
| Open | 8.41 |
| Previous Close | 8.54 |
| Day's Range | 8.01 - 8.69 |
| 52-Week Range | 5.14 - 33.68 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 46.00 (+469.31%) |
| Earnings Date | Mar 11, 2026 |
About UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Financial Performance
In 2024, Upstream Bio's revenue was $2.37 million, a decrease of -0.42% compared to the previous year's $2.38 million. Losses were -$76.40 million, 99.7% more than in 2023.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for UPB stock is "Strong Buy." The 12-month stock price target is $46.0, which is an increase of 469.31% from the latest price.
News
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns
Upstream Bio Inc. (NASDAQ: UPB) shares are trading lower during Friday's session as the stock reacts to recent developments in its clinical trials.
Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts
The stock gave up its gains and is falling, probably on profit booking.
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing –
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
– Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET – – Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET –
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study
Upstream Bio, Inc. achieved statistical significance in the phase 2 VIBRANT trial for Verekitug in treating patients with CRSwNP, supporting a Buy rating. Verekitug's once-every-12-weeks dosing offers...
Upstream Bio to Participate in Upcoming December Investor Conferences
WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endp...
Upstream Bio to Participate in Upcoming November Investor Conferences
WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodi...
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirato...
Upstream Bio, Inc. - Special Call
Upstream Bio, Inc. - Special Call Company Participants Meggan Buckwell E. Sutherland - CEO & Director Aaron Deykin - Chief Medical Officer and Head of Research & Development Conference Call Participan...
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjus...
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirato...
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in Ju...
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD –
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepeluma...
Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio Appoints Stacy Price as Chief Technology Officer
WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory...
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial o...
Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent
Upstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of...
3 Dividend Giants To Buy As Tariffs Hit Stocks
This year's tariff storms have hit tech stocks, semiconductor stocks and even metal and mining stocks. Now, they're starting to hit dividend stocks, too.
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –
Upstream Bio to Present at Upcoming March Investor Conferences
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...